{"id":"abatacept-infusion","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Infection (upper respiratory, urinary tract)"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Hypertension"},{"rate":"2-5","effect":"Serious infections"}]},"_chembl":{"chemblId":"CHEMBL1201823","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abatacept (CTLA4-Ig) works by interrupting the second signal required for full T-cell activation. It binds to CD80 and CD86 molecules on antigen-presenting cells, preventing their interaction with CD28 on T cells. This selective costimulation blockade reduces proliferation and activation of T cells, leading to decreased production of inflammatory cytokines and reduced autoimmune responses.","oneSentence":"Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:28.788Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Systemic lupus erythematosus"}]},"trialDetails":[{"nctId":"NCT07388563","phase":"PHASE1","title":"Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Lymphoma, T Cell, Peripheral, T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":20},{"nctId":"NCT00920972","phase":"PHASE1, PHASE2","title":"Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2001-12","conditions":"Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies","enrollment":220},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06918990","phase":"PHASE2","title":"Treatment of Antibody-Mediated Rejection (ABMR) With CarBel","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-15","conditions":"Kidney Transplant Rejection","enrollment":25},{"nctId":"NCT06055608","phase":"PHASE2","title":"Advancing Transplantation Outcomes in Children","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-05-22","conditions":"Kidney Transplant","enrollment":200},{"nctId":"NCT03929601","phase":"PHASE2","title":"Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-10-30","conditions":"Type 1 Diabetes Mellitus","enrollment":74},{"nctId":"NCT03504241","phase":"PHASE1","title":"Tolerance by Engaging Antigen During Cellular Homeostasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-30","conditions":"Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient","enrollment":8},{"nctId":"NCT05621759","phase":"PHASE2","title":"Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-09-07","conditions":"Graft Vs Host Disease","enrollment":27},{"nctId":"NCT07366801","phase":"PHASE2, PHASE3","title":"Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2025-09-03","conditions":"Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk","enrollment":64},{"nctId":"NCT04827979","phase":"PHASE1, PHASE2","title":"Daratumumab and Belatacept for Desensitization","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-01","conditions":"Highly Sensitized Prospective Kidney Transplant Recipients","enrollment":19},{"nctId":"NCT04786067","phase":"PHASE4","title":"Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-07-28","conditions":"Kidney Transplant Immunosuppression","enrollment":25},{"nctId":"NCT06145282","phase":"PHASE1, PHASE2","title":"Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2023-12-28","conditions":"Sickle Cell Disease","enrollment":6},{"nctId":"NCT04955366","phase":"PHASE2","title":"Abatacept Conversion in Kidney Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-09-22","conditions":"Renal Transplant Recipient","enrollment":87},{"nctId":"NCT05335928","phase":"PHASE3","title":"Abatacept in Immune Checkpoint Inhibitor Myocarditis","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-07-02","conditions":"Myocarditis Acute, Cancer","enrollment":390},{"nctId":"NCT05822583","phase":"PHASE4","title":"Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-07-06","conditions":"COVID-19","enrollment":285},{"nctId":"NCT04046549","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-10-30","conditions":"Allografts, Rejection; Transplant, Kidney, Transplant Rejection","enrollment":25},{"nctId":"NCT05289167","phase":"PHASE1, PHASE2","title":"Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwell Health","startDate":"2022-03-13","conditions":"Graft-versus-host Disease","enrollment":74},{"nctId":"NCT04503616","phase":"PHASE1, PHASE2","title":"Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-09-16","conditions":"Graft-versus-host Disease","enrollment":46},{"nctId":"NCT03086343","phase":"PHASE3","title":"A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-09","conditions":"Rheumatoid Arthritis (RA)","enrollment":657},{"nctId":"NCT03652961","phase":"PHASE4","title":"Rheumatoid Arthritis Memory B Cells and Abatacept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-02","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT01773707","phase":"PHASE2","title":"CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2013-03","conditions":"Abnormal Glucose Tolerance, Type 1 Diabetes","enrollment":212},{"nctId":"NCT03733067","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-11-30","conditions":"CTLA4 Haploinsufficency, Chronic Cytopenia","enrollment":""},{"nctId":"NCT02213068","phase":"PHASE4","title":"Belatacept 3 Month Post Transplant Conversion Study","status":"COMPLETED","sponsor":"Lorenzo Gallon","startDate":"2014-07","conditions":"Transplant; Failure, Kidney, EBV","enrollment":28},{"nctId":"NCT04472494","phase":"PHASE2","title":"Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2020-10-14","conditions":"COVID-19, SARS-CoV-2","enrollment":61},{"nctId":"NCT01491815","phase":"PHASE4","title":"Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2012-12-14","conditions":"Rheumatoid Arthritis","enrollment":812},{"nctId":"NCT02466581","phase":"PHASE4","title":"Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2015-02-03","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT01729494","phase":"PHASE4","title":"Belatacept Early Steroid Withdrawal Trial","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2012-09","conditions":"Renal Transplantation","enrollment":316},{"nctId":"NCT02137239","phase":"PHASE2","title":"Regimen Optimization Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12-31","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT01835470","phase":"PHASE3","title":"Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-08-09","conditions":"Juvenile Idiopathic Arthritis","enrollment":23},{"nctId":"NCT04733131","phase":"","title":"Long-term Outcomes After Conversion to Belatacept","status":"UNKNOWN","sponsor":"Paris Translational Research Center for Organ Transplantation","startDate":"2004-01-01","conditions":"Kidney Transplant Failure and Rejection, Immunosuppression, Graft Loss","enrollment":324},{"nctId":"NCT03714022","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-11-09","conditions":"Rheumatoid Arthritis","enrollment":140},{"nctId":"NCT01820572","phase":"PHASE3","title":"A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-03-27","conditions":"Kidney Transplantation","enrollment":446},{"nctId":"NCT01856257","phase":"PHASE2","title":"Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-07","conditions":"Primary Renal Allograft Candidate, Kidney Transplantation","enrollment":71},{"nctId":"NCT04000698","phase":"PHASE3","title":"Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2019-10-15","conditions":"Refractory Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia","enrollment":25},{"nctId":"NCT01315938","phase":"PHASE2","title":"Abatacept Treatment in Polymyositis and Dermatomyositis","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2011-01","conditions":"Polymyositis, Dermatomyositis","enrollment":20},{"nctId":"NCT04572620","phase":"","title":"Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2020-09-07","conditions":"Interstitial Lymphocytic Lung Disease","enrollment":30},{"nctId":"NCT02560558","phase":"PHASE4","title":"Bela 8 Week Dosing","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-09","conditions":"Kidney Transplantation","enrollment":166},{"nctId":"NCT00505375","phase":"PHASE2","title":"Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2008-02","conditions":"Type 1 Diabetes Mellitus","enrollment":112},{"nctId":"NCT00739960","phase":"PHASE2","title":"Safety Study of Abatacept to Treat Refractory Sarcoidosis","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2008-08","conditions":"Sarcoidosis","enrollment":1},{"nctId":"NCT00565773","phase":"PHASE2","title":"Belatacept Post Depletional Repopulation to Facilitate Tolerance","status":"COMPLETED","sponsor":"Allan D Kirk, MD, PhD","startDate":"2007-12","conditions":"Organ Transplantation","enrollment":40},{"nctId":"NCT04120831","phase":"PHASE2","title":"TOLERA: Tolerance Enhancement in RA","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2019-10-07","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT03375138","phase":"PHASE1","title":"A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-12-04","conditions":"Healthy Volunteers","enrollment":84},{"nctId":"NCT03084419","phase":"PHASE2","title":"APRIL (AbatacePt in Rheumatoid Arthritis-ILD)","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2018-06-26","conditions":"Rheumatoid Arthritis, Interstitial Lung Disease","enrollment":30},{"nctId":"NCT01279954","phase":"PHASE2","title":"Abatacept in the Treatment of Uveitis","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2012-01","conditions":"Uveitis","enrollment":10},{"nctId":"NCT02130817","phase":"PHASE4","title":"Belatacept in Kidney Transplantation of Moderately Sensitized Patients","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2014-09-24","conditions":"End Stage Renal Disease, Antibody Mediated Rejection","enrollment":""},{"nctId":"NCT01638715","phase":"PHASE4","title":"A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-05","conditions":"Rheumatoid Arthritis","enrollment":115},{"nctId":"NCT01496417","phase":"NA","title":"Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores","status":"COMPLETED","sponsor":"University of Maryland","startDate":"2012-03","conditions":"End-Stage Renal Disease","enrollment":20},{"nctId":"NCT00556439","phase":"PHASE2","title":"Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis","status":"COMPLETED","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2008-12","conditions":"Takayasu's Arteritis, Giant Cell Arteritis","enrollment":97},{"nctId":"NCT02103855","phase":"PHASE4","title":"Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2014-06","conditions":"Nephrotoxicity","enrollment":6},{"nctId":"NCT02078193","phase":"PHASE4","title":"Efficacy of Belatacept in Reducing DSA","status":"COMPLETED","sponsor":"East Carolina University","startDate":"2013-11","conditions":"Kidney Transplantation","enrollment":3},{"nctId":"NCT01791491","phase":"PHASE2","title":"Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-05-09","conditions":"Kidney Transplant","enrollment":16},{"nctId":"NCT01758198","phase":"PHASE4","title":"Abatacept Post-marketing Clinical Study in Japan","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-04-11","conditions":"Rheumatoid Arthritis","enrollment":405},{"nctId":"NCT02232880","phase":"PHASE2","title":"Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2014-08","conditions":"Hypertension","enrollment":1},{"nctId":"NCT01837043","phase":"PHASE2","title":"Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function","status":"UNKNOWN","sponsor":"Nair, Vinay, D.O.","startDate":"2013-06","conditions":"Delayed Graft Function, Kidney Transplant","enrollment":90},{"nctId":"NCT00095173","phase":"PHASE3","title":"BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2003-12","conditions":"Juvenile Rheumatoid Arthritis","enrollment":214},{"nctId":"NCT02600468","phase":"","title":"Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":671},{"nctId":"NCT00402168","phase":"PHASE2","title":"A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-01","conditions":"Renal Transplant","enrollment":173},{"nctId":"NCT01295151","phase":"PHASE4","title":"SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.","status":"COMPLETED","sponsor":"Julia Brown","startDate":"2011-08","conditions":"Rheumatoid Arthritis","enrollment":122},{"nctId":"NCT00569803","phase":"PHASE1","title":"Subcutaneous Pharmacokinetics of Belatacept","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-12","conditions":"Transplantation","enrollment":153},{"nctId":"NCT00468403","phase":"PHASE2","title":"LEA29Y (Belatacept) Emory Edmonton Protocol","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-10","conditions":"Type 1 Diabetes Mellitus","enrollment":10},{"nctId":"NCT00774852","phase":"PHASE2","title":"Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-11","conditions":"Lupus Nephritis, Lupus Erythematosus, Systemic","enrollment":137},{"nctId":"NCT00468208","phase":"PHASE1, PHASE2","title":"Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2008-02","conditions":"Wegener's Granulomatosis","enrollment":20},{"nctId":"NCT00559585","phase":"PHASE3","title":"Methotrexate-Inadequate Response Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-01","conditions":"Rheumatoid Arthritis (RA)","enrollment":2492},{"nctId":"NCT02500498","phase":"","title":"Safety Profile of Nulojix in Home Infusion Settings","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-10","conditions":"Rheumatoid Arthritis","enrollment":37},{"nctId":"NCT00482066","phase":"PHASE2","title":"Abatacept in ANCA Associated Vasculitis","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2007-11","conditions":"ANCA-associated Vasculitis","enrollment":7},{"nctId":"NCT00095147","phase":"PHASE3","title":"Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-02","conditions":"Rheumatoid Arthritis","enrollment":431},{"nctId":"NCT00455013","phase":"PHASE2","title":"A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-07","conditions":"Disorder Related to Renal Transplantation","enrollment":93},{"nctId":"NCT01001832","phase":"PHASE2, PHASE3","title":"Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Rheumatoid Arthritis","enrollment":118},{"nctId":"NCT00578448","phase":"PHASE2","title":"Belatacept Pharmacokinetic Trial in Renal Transplantation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-03","conditions":"Renal Transplantation","enrollment":14},{"nctId":"NCT00035555","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-03","conditions":"Graft Rejection, Kidney Transplantation, Renal Transplantation","enrollment":230},{"nctId":"NCT00705367","phase":"PHASE1","title":"Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-08","conditions":"Lupus Nephritis","enrollment":13},{"nctId":"NCT01314495","phase":"PHASE2","title":"Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis","status":"WITHDRAWN","sponsor":"Julian M. Mackay-Wiggan","startDate":"2011-09","conditions":"Alopecia Totalis/Universalis","enrollment":""},{"nctId":"NCT00534313","phase":"PHASE2","title":"Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11","conditions":"Psoriatic Arthritis","enrollment":191},{"nctId":"NCT00162266","phase":"PHASE2","title":"Abatacept With Methotrexate- Phase IIB","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2000-10","conditions":"Rheumatoid Arthritis","enrollment":524},{"nctId":"NCT00124982","phase":"PHASE3","title":"Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-04","conditions":"Rheumatoid Arthritis","enrollment":1286},{"nctId":"NCT00420199","phase":"PHASE3","title":"A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-05","conditions":"Active Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT01339481","phase":"","title":"A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-02","conditions":"Rheumatoid Arthritis","enrollment":26},{"nctId":"NCT00048932","phase":"PHASE3","title":"A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":1795},{"nctId":"NCT00345748","phase":"PHASE2","title":"A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-06","conditions":"Rheumatoid Arthritis","enrollment":194},{"nctId":"NCT00277225","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1995-11","conditions":"Psoriasis Vulgaris","enrollment":32},{"nctId":"NCT00035529","phase":"PHASE2","title":"A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2001-11","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT00162279","phase":"PHASE2","title":"The Study of Abatacept in Combination With Etanercept","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2000-10","conditions":"Rheumatoid Arthritis","enrollment":141}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ASTHMA"},{"count":1,"reaction":"BRONCHITIS"},{"count":1,"reaction":"CHILLS"},{"count":1,"reaction":"CONDITION AGGRAVATED"}],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"abatacept infusion","genericName":"abatacept infusion","companyName":"University of Minnesota","companyId":"university-of-minnesota","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abatacept is a protein-based inhibitor of the T-lymphocyte activation antigen CD86, used to treat various conditions including rheumatoid arthritis and chronic cytopenia in CTLA4 haploinsufficiency. It is administered via infusion as part of clinical trials for these conditions, with its efficacy and safety being studied in randomized, double-blind trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}